A XM não fornece serviços a residentes nos Estados Unidos da América.

A XM não fornece serviços a residentes nos Estados Unidos da América.
N
N

Novartis

Notícias

Reuters - Há 1 dia

EU regulator requires secondary cancer risk warning for T therapies

UPDATE 3-EU regulator requires secondary cancer risk warning for CAR-T therapies Changes headline, adds background in paragraphs 3, 5 & 6 June 14 (Reuters) - The European health regulator said on Friday cancer cell therapies known as CAR-T treatments must include a written warning of an associated risk for secondary blood cancers in patients who use them and that patients should be monitored for life.
G
N
Reuters - Há 1 dia

EU regulator mandates label updates on T cancer therapies

EU regulator mandates label updates on CAR-T cancer therapies June 14 (Reuters) - The European health regulator said on Friday product information for a class of cancer therapies known as CAR-T treatments would be required to highlight risk of secondary cancers in patients who use them, ending a five-month safety review. Reporting by Mariam Sunny i
G
N
Reuters - Há 5 dias

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V
Reuters - Há 6 dias

Swiss stocks - Factors to watch on June 10

Swiss stocks - Factors to watch on June 10 ZURICH/GDANSK, June 10(Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS * Roche ROG.S - European Commission approves Roche’s Alecensa * Barry Callebaut AG BARN.S - Places New EUR 700 Mln Denominated Bond * Dormakaba Holding AG DOKA.S - To Divest Its Sub-Saharan African Business * Metall Zug AG METN.S , METN.S - Announces Start of JV ANALYSTS' VIEWS BARRY CALLEBAUT AG BARN.S - BERENBERG RAISES TARG
N
N
R
S
Reuters - Há 1 semana

Law firm defends work in $5.6 bln card fee case after disclosing fake claims

Law firm defends work in $5.6 bln card fee case after disclosing fake claims By Mike Scarcella June 7 (Reuters) - A law firm that earlier said it unknowingly submitted fake claims as part of a $5.6 billion settlement with Visa and MasterCard told a U.S. judge on Thursday that other parties had also submitted fraudulent material in the case. Responding to a request for more information from the Brooklyn judge overseeing the antitrust case, New York-founded Milberg Coleman Bryson Phillips Grossman
N
V
Reuters - Há 1 semana

US judge orders probe of Novartis $30 mln settlement claims process

US judge orders probe of Novartis $30 mln settlement claims process By Brendan Pierson June 6 (Reuters) - A federal judge has ordered a probe of the claims distribution process in a $30 million settlement by Novartis NOVN.S with consumers and health plans in an antitrust class action over its hypertension drug Exforge, citing concerns about its integrity.
N
Reuters - Há 1 semana

Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists

INSIGHT-Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists By Kirsty Needham, Andrew Silver SYDNEY/SHANGHAI, June 6 (Reuters) - Employees of drugmaker WuXi AppTec, under U.S. scrutiny for its links to the Chinese military, co-invented altitude sickness treatments with People's Liberation Army (PLA) scientists, according to public patent records and science papers reviewed by Reuters.
N
Reuters - Há 1 semana

Novartis, Roche unit and others face Italy antitrust probe over eye drug

UPDATE 3-Novartis, Roche unit and others face Italy antitrust probe over eye drug Adds Biogen comment in last paragraph ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis NOVN.S and Roche-controlled ROG.S Genentech for having potentially restricted competition in the sale of an eye drug.
B
N
R
Reuters - Há 1 semana

Novartis and others face Italy antitrust probe over eye drug

Novartis and others face Italy antitrust probe over eye drug ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis NOVN.S , for having potentially restricted competition in the sale of a drug for eye conditions. Samsung Bioepis, Biogen, Genentech and Novartis, and some of their Italian, Dutch and UK units, allegedly coordinated their commercial strategies to delay the launch in Italy of Byooviz, a d
B
N
R
Reuters - Há 1 semana

Cytokinetics rises; CEO confirms prior M&A interest in company

BUZZ-Cytokinetics rises; CEO confirms prior M&A interest in company ** Shares of drug developer Cytokinetics CYTK.O rise 9.5%to $53 ** CEO Robert Blum said at an industry conference that CYTK was engaged in strategic talks with potential partners for its experimental heart disease drug, aficamten, throughout 2023 ** CYTK was approached by one of the third parties with whom they had previously engaged with regarding acquisition of the company, Blum says ** Blum says CYTK's board was supportive of
N
Reuters - Há 2 semanas

Lawsuits pile up over state laws on discounts for hospitals' contract pharmacies

Lawsuits pile up over state laws on discounts for hospitals' contract pharmacies By Brendan Pierson June 3 (Reuters) - The pharmaceutical industry has filed at least four lawsuits this year challenging state laws requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies that contract with hospitals and clinics serving low-income populations.
N
Reuters - Há 2 semanas

Swiss stocks - Factors to watch on June 3

CORRECTED-Swiss stocks - Factors to watch on June 3 Removes rating changes with wrong date ZURICH/GDANSK, June 3 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: UBS UBSG.S UBS on Friday completed the merger of the main parent companies of the Swiss bank and Credit Suisse, which it acquired last year after its longtime rival collapsed, putting an end to one of the bastions of the country's financial sector.
G
N
R
S
U
S
T
Reuters - Há 2 semanas

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes June 2 (Reuters) - Treatment with Bristol Myers Squibb's BMY.N immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday.
N
Reuters - Há 2 semanas

Novartis says phase III trial shows Kisqali product reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease

BRIEF-Novartis says phase III trial shows Kisqali product reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease May 31 (Reuters) - NOVARTIS AG NOVN.S : LATEST ANALYSIS OF NOVARTIS NATALEE STUDY SHOWS KISQALI® REDUCES RISK OF CANCER RECURRENCE FOR EARLY BREAST CANCER PATIENTS WITH HIGH-RISK NODE-NEG
N
Reuters - Há 2 semanas

Novartis Scemblix Phase III Data Shows Superior Efficacy With Favorable Safety & Tolerability Profile In Adults With Newly Diagnosed Cml

BRIEF-Novartis Scemblix Phase III Data Shows Superior Efficacy With Favorable Safety & Tolerability Profile In Adults With Newly Diagnosed Cml May 31 (Reuters) - Novartis AG NOVN.S : NOVARTIS SCEMBLIX PHASE III DATA SHOWS SUPERIOR EFFICACY WITH FAVORABLE SAFETY & TOLERABILITY PROFILE IN ADULTS WITH NEWLY DIAGNOSED CML NOVARTIS: SCEMBLIX (ASCIMINIB)
N
Reuters - Há 2 semanas

Novartis leukemia drug more effective than older treatments in trial

Novartis leukemia drug more effective than older treatments in trial By Christy Santhosh May 31 (Reuters) - Swiss drugmaker Novartis NOVN.S said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs in a late-stage study with details presented on Friday.
N
P
Reuters - Há 2 semanas

Swiss stocks - Factors to watch on May 31

Swiss stocks - Factors to watch on May 31 May 31 - Here are some of the main factors that may affect Swiss stocks on Friday: NOVARTIS AG NOVN.S Novartis sues Maryland over law mandating discounts for hospitals' outside pharmacies ( Full story ) The company also says phase III data confirm sustained efficacy and long-term safety Of oral remibrutinib in chronic spontaneous urticaria ( Full story ) COMPANY STATEMENTS Meyer Burger Technology AG MBTN.S - Board Of Directors Proposes Reverse Share Spli
C
N
U
Reuters - Há 2 semanas

Novartis Says Phase III Data Confirm Sustained Efficacy And Long-Term Safety Of Oral Remibrutinib In Chronic Spontaneous Urticaria

BRIEF-Novartis Says Phase III Data Confirm Sustained Efficacy And Long-Term Safety Of Oral Remibrutinib In Chronic Spontaneous Urticaria May 30 (Reuters) - Novartis AG NOVN.S : NOVARTIS PHASE III DATA CONFIRM SUSTAINED EFFICACY AND LONG-TERM SAFETY OF ORAL REMIBRUTINIB IN CHRONIC SPONTANEOUS URTICARIA NOVARTIS - INTENDS TO SUBMIT REMIBRUTINIB FOR A
N
Reuters - Há 2 semanas

Novartis sues Maryland over law mandating discounts for hospitals' outside pharmacies

Novartis sues Maryland over law mandating discounts for hospitals' outside pharmacies By Brendan Pierson May 30 (Reuters) - Novartis NOVN.S has filed a lawsuit seeking to block a Maryland law that would require drugmakers to offer discounts on drugs dispensed by third-party pharmacies that contract with hospitals and clinics serving low-income populations.
N
Reuters - Há 2 semanas

Currys, Ovhcloud, Whitbread

EUROPE RESEARCH ROUNDUP-Currys, Ovhcloud, Whitbread May 30 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Currys, Ovhcloud and Whitbread, on Thursday. HIGHLIGHTS * Anglo American AAL.L : Jefferies cuts to hold from buy * Currys Plc CURY.L : Berenberg raises to buy from hold * Ovhcloud OVH.PA : Stifel cuts to hold from buy * Solvay SOLB.BR : Morgan Stanley raises to equal weight from underweight * Whitbread WTB.L : Berenberg cuts t
A
A
B
B
E
F
G
K
L
L
M
M
N
P
R
S
W
W
H
A
A
A
M

Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.